Literature DB >> 22698651

Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients.

Quan Yuan, Liu-Wei Song, Chun-Jen Liu, Zhuo Li, Ping-Guo Liu, Cheng-Hao Huang, Yan Yan, Sheng-Xiang Ge, Ying-Bin Wang, Cheng-Yuan Peng, Jun Zhang, Jia-Horng Kao, Ding-Shinn Chen, Pei-Jer Chen, Ning-Shao Xia.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22698651     DOI： 10.1136/gutjnl-2012-302656

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  27 in total

1.  Looking into the crystal ball: biomarkers for outcomes of HBV infection.

Authors:  Hung-Chih Yang; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2016-01-05       Impact factor: 6.047

2.  The impact of hepatitis B core antibody levels on HBV reactivation after allogeneic hematopoietic SCT: an 11-year experience at a single center.

Authors:  S K Bae; T Gushima; N Saito; I Yamanaka; T Shimokawa; Y Matsuo; S Yoshida; I Kawano; H Henzan; S Shimoda; T Eto; K Takahashi
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

3.  Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels.

Authors:  Xihua Fu; Haibo Lou; Fang Chen; Xueping Gao; Zhanzhou Lin
Journal:  Clin Exp Med       Date:  2020-02-12       Impact factor: 3.984

4.  Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients.

Authors:  Chang-Tai Wang; Ya-Fei Zhang; Bing-Hu Sun; Yu Dai; Hui-Lan Zhu; Yuan-Hong Xu; Meng-Ji Lu; Dong-Liang Yang; Xu Li; Zhen-Hua Zhang
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

5.  Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

Authors:  Carla S Coffin; Scott K Fung; Fernando Alvarez; Curtis L Cooper; Karen E Doucette; Claire Fournier; Erin Kelly; Hin Hin Ko; Mang M Ma; Steven R Martin; Carla Osiowy; Alnoor Ramji; Edward Tam; Jean Pierre Villeneuve
Journal:  Can Liver J       Date:  2018-12-25

6.  Hepatitis B virus reactivation during temozolomide administration for malignant glioma.

Authors:  Takuhiro Shoji; Masayuki Kanamori; Jun Inoue; Ryuta Saito; Yoshinari Osada; Yoshiteru Shimoda; Masashi Chonan; Hiroshi Uenohara; Atsushi Masamune; Teiji Tominaga
Journal:  Int J Clin Oncol       Date:  2020-10-28       Impact factor: 3.402

7.  Baseline quantitative hepatitis B core antibody could strongly predict survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Guosheng Yuan; Yuchen Zhou; Hao Zhang; Junjie Wang; Nianhuan Yang; Yabing Guo; Dinghua Yang; Yuanping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 8.  Emerging hepatitis B virus infection in vaccinated populations: a rising concern?

Authors:  Tung-Hung Su; Pei-Jer Chen
Journal:  Emerg Microbes Infect       Date:  2012-09-19       Impact factor: 7.163

9.  Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease.

Authors:  Quan Yuan; Liu-Wei Song; Daniela Cavallone; Francesco Moriconi; Beatrice Cherubini; Piero Colombatto; Filippo Oliveri; Barbara Agata Coco; Gabriele Ricco; Ferruccio Bonino; James Wai Kuo Shih; Ning-Shao Xia; Maurizia Rossana Brunetto
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

Review 10.  Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management.

Authors:  Alicia Vachon; Carla Osiowy
Journal:  Viruses       Date:  2021-05-21       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.